Jessi Hammond
Payments from drug & device makers
Across 128 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$678
- Amgen$202
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$172
- Novartis$130
- Lilly USA, LLC$114
- Otsuka America Pharmaceutical, Inc.$88
- plus $767 from 19 others
What the payments were for
- Food & beverage$2,151100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $678 |
| Amgen | 13 | $202 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $172 |
| Novartis | 9 | $130 |
| Lilly USA, LLC | 7 | $114 |
| Otsuka America Pharmaceutical, Inc. | 3 | $88 |
| Edwards Lifesciences | 3 | $81 |
| Pfizer | 4 | $77 |
| AstraZeneca | 5 | $74 |
| GSK | 5 | $73 |
| AbbVie | 4 | $72 |
| Esperion Therapeutics, Inc. | 5 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Sumitomo Pharma America, Inc. | 4 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Medtronic | 1 | $30 |
| Bausch Health US, LLC | 2 | $28 |
| Boehringer Ingelheim | 2 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Mckesson Medical-surgical, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Seqirus USA Inc | 1 | $12 |
How this compares
$2,151 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 35 | $32,464 |
| OzempicSemaglutide | 27 | $28,593 |
| TrulicityDulaglutide | 23 | $23,264 |
| MounjaroTirzepatide | 13 | $17,018 |
| EliquisApixaban | 21 | $13,746 |
| Ezetimibe | 32 | $1,029 |
| Celecoxib | 21 | $937 |
| Fluticasone Propionate | 46 | $809 |
| Rosuvastatin Calcium | 41 | $653 |
| Gabapentin | 36 | $577 |
| Levothyroxine Sodium | 49 | $518 |
| Pregabalin | 13 | $483 |
| Duloxetine Hcl | 25 | $476 |
| Atorvastatin Calcium | 39 | $453 |
| Tamsulosin Hcl | 26 | $389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $114 | $40,28236 claims |
| Boehringer IngelheimJardiance | $24 | $32,46435 claims |
| Novo NordiskOzempic | $678 | $28,59327 claims |
| PfizerEliquis | $77 | $13,74621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Macon
- Villanueva SpiveyMacon$18K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.